USE OF HDACI AND PD-1/PD-LI BLOCKADE TO ENHANCE CYTOLYTIC ACTIVITY OF EX VIVO EXPANDED NK CELLS AGAINST NEUROBLASTOMA

被引：0
|
作者：
Shen, S. [1 ,2 ,3 ]
Dolnikov, A. [1 ,2 ,3 ]
O'Brien, T. [1 ,2 ,3 ]
机构：
[1] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia
[2] Univ New S Wales, Fac Med, Sydney, NSW, Australia
[3] Childrens Canc Inst Med Res, Sydney, NSW, Australia
来源：
CYTOTHERAPY | 2016年 / 18卷 / 06期
关键词：
D O I：
暂无
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
185
引用
收藏
页码：S64 / S64
页数：1
相关论文
共 50 条
  • [21] Integrating Systems Biology and an Ex Vivo Human Tumor Model Elucidates PD-1 Blockade Response Dynamics
    Smalley, Munisha
    Przedborski, Michelle
    Thiyagarajan, Saravanan
    Pellowe, Moriah
    Verma, Amit
    Brijwani, Nilesh
    Datta, Debika
    Jain, Misti
    Shanthappa, Basavaraja U.
    Kapoor, Vidushi
    Gopinath, Kodaganur S.
    Doval, D. C.
    Sabitha, K. S.
    Taroncher-Oldenburg, Gaspar
    Majumder, Biswanath
    Majumder, Pradip
    Kohandel, Mohammad
    Goldman, Aaron
    ISCIENCE, 2020, 23 (06)
  • [22] Circulating PD-1 (+) cells may participate in immune evasion in peripheral T-cell lymphoma and chidamide enhance antitumor activity of PD-1 (+) cells
    Zhang, Wei
    Shen, Haorui
    Zhang, Yan
    Wang, Wei
    Hu, Shaoxuan
    Zou, Dongmei
    Zhou, Daobin
    CANCER MEDICINE, 2019, 8 (05): : 2104 - 2113
  • [23] Targeting metabolic vulnerabilities of MDSCs to enhance the anti-tumor activity of PD-1 blockade in melanoma
    Zheng, B.
    Kim, S.
    Li, M.
    Trousil, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S137 - S137
  • [24] INTRATUMOR-INFILTRATING NATURAL KILLER CELLS PREDICT FAVORABLE PROGNOSIS AND RESPONSE TO PD-1 BLOCKADE IN NEUROBLASTOMA
    Song, Mengjia
    Lu, Suying
    Wang, Juan
    Huang, Junting
    Zhu, Jia
    Zhang, Yizhuo
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S150 - S151
  • [25] PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
    de Coana, Yago Pico
    Wolodarski, Maria
    Avila, Irene van der Haar
    Nakajima, Takahiro
    Rentouli, Stamatina
    Lundqvist, Andreas
    Masucci, Giuseppe
    Hansson, Johan
    Kiessling, Rolf
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [26] Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy
    Kumar, Alok
    Chamoto, Kenji
    Chowdhury, Partha S.
    Honjo, Tasuku
    ELIFE, 2020, 9
  • [27] The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector
    Dong, Wenjuan
    Wu, Xiaojin
    Ma, Shoubao
    Wang, Yufeng
    Nalin, Ansel P.
    Zhu, Zheng
    Zhang, Jianying
    Benson, Don M.
    He, Kai
    Caligiuri, Michael A.
    Yu, Jianhua
    CANCER DISCOVERY, 2019, 9 (10) : 1422 - 1437
  • [28] iPSC-Derived NK Cells and Anti-PD-1 Antibody Synergize to Enhance T Cell Cytokine and Cytolytic Responses Against Multiple Tumors
    Cichocki, Frank
    Bjordahl, Ryan
    Gaidarova, Svetlana
    Mahmood, Sajid
    Rogers, Paul
    Ge, Moyar Q.
    Kaufman, Dan S.
    Cooley, Sarah
    Valamehr, Bahram
    Miller, Jeffrey S.
    BLOOD, 2018, 132
  • [29] PD-1 checkpoint blockade in advanced melanoma patients: Neutrophils, NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates
    de Coana, Yago Pico
    Wolodarski, Maria
    Avila, Irene van der Haar
    Nakajima, Takahiro
    Rentouli, Stamatina
    Lundqvist, Andreas
    Masucci, Giuseppe
    Hansson, Johan
    Kiessling, Rolf
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [30] PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets
    Davis, Zachary
    Felices, Martin
    Lenvik, Todd R.
    Badal, Sujan
    Hinderlie, Peter
    Blazar, Bruce R.
    Vallera, Daniel A.
    Miller, Jeffrey S.
    BLOOD, 2019, 134
12345